Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 09 2023 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2023
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
CONTENTS
On January 9, 2023, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Signs Agreement to
Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center.” A copy of this press release is furnished
herewith as Exhibit 99.1 and incorporated by reference herein.
The first, second, fourth,
fifth and sixth paragraphs and the section titled “Forward-Looking Statements” in the press release attached hereto as Exhibit
99.1 are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-266047, File No. 333-233417
and File No. 333-248670) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: January 9, 2023 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and
Chief Financial Officer |
2
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2023 to May 2024